NCT00116311

Brief Summary

The purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. We hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects. We also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. We believe that adenosine receptor expression will be upregulated after allergen inhalation. Both hypotheses are being tested in sputum and peripheral blood.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2005

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 29, 2005

Completed
2 days until next milestone

Study Start

First participant enrolled

July 1, 2005

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2007

Completed
Last Updated

March 21, 2007

Status Verified

March 1, 2007

First QC Date

June 28, 2005

Last Update Submit

March 20, 2007

Conditions

AsthmaHealthy

Keywords

Adenosine receptorsasthmasputumperipheral bloodhealthy

Interventions

allergen inhalationBEHAVIORAL
withdrawal of medicationBEHAVIORAL
sputum inductionPROCEDURE

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Clinical diagnosis of asthma
  • Steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication
  • FEV1 \> 70% of predicted
  • Positive skin prick test for house dust mite, cat or grass pollen
  • PC20 methacholine or histamine \< 8 mg/ml

You may not qualify if:

  • Use of systemic steroids in the previous 6 weeks
  • Asthma exacerbations in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago
  • No airway complaints
  • FEV1 \> 90% of predicted
  • Negative skin prick test
  • PC20 methacholine or histamine \> 8 mg/ml
  • Use of steroids in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Groningen, Department of Pulmonology

Groningen, 9713 GZ, Netherlands

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Dirkje S Postma, prof. MD PhD

    University Medical Center Groningen, Department of Pulmonology, hanzeplein 1, 9713 GZ Groningen, The Netherlands

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
OTHER
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 28, 2005

First Posted

June 29, 2005

Study Start

July 1, 2005

Study Completion

February 1, 2007

Last Updated

March 21, 2007

Record last verified: 2007-03

Locations

NL(1)